Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Announces 16 APIs as Candidates for Switch-OTC Status: None for Lifestyle Diseases
The Ministry of Health, Labor and Welfare (MHLW) announced on its website on December 9 a list of 16 active pharmaceutical ingredients (APIs) for which switch-OTC status has been requested by scientific societies, organizations, companies, and consumers (individuals) under the…
To read the full story
Related Article
- Vonoprazan Gets Panel Backing for Rx-to-OTC Switch
August 25, 2025
- All Three PPI Switch OTCs Approved following MHLW Panel OK
July 14, 2025
- Pariet’s Nonprescription Versions Approved 6 Years after Discussions Start
March 25, 2025
- Health Ministry Panel Endorses RX-to-OTC Switches of 3 PPIs
December 23, 2024
- Japan Panel Backs Rx-to-OTC Switch of 4 PPIs
July 30, 2024
- Japan Resumes Debate on Rx-to-OTC Switch of PPIs after Over 5 Years
March 22, 2024
- Council Holds Off Nonprescription Switches of PPIs Despite Public Support
December 10, 2018
- MHLW Panel Rebuffs Nonprescription Switches of 3 PPIs
August 3, 2018
- Healthcare Experts at Odds over Nonprescription Switches of 3 PPIs
March 20, 2018
- MHLW Council Recommends Switching of 4 APIs; Switching of Levonorgestrel for Emergency Contraception Disapproved
July 28, 2017
- 6 APIs Added to List of “Switch OTC” Candidates: MHLW
June 26, 2017
- New Scheme on Switch OTC Gets Underway
April 14, 2016
REGULATORY
- LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
- MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
- MHLW to Allow OTC Drugs to Match Prescription Doses under Specific Conditions
February 5, 2026
- Japan Launches Biotechnology Working Group, Roadmap Draft Due in April
February 4, 2026
- Japan Panel Backs Nonprescription Switch of Second Emergency Contraceptive
February 4, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…